Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 148.70M | 231.10M | 140.90M | 222.20M | 194.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 148.70M | 231.10M | 140.90M | 222.20M | 194.70M |
| Cost of Revenue | 94.00M | 99.00M | 80.20M | 102.80M | 123.00M |
| Gross Profit | 54.70M | 132.10M | 60.70M | 119.40M | 71.70M |
| SG&A Expenses | 61.60M | 28.30M | 44.00M | 52.70M | 70.70M |
| Depreciation & Amortization | 16.30M | 16.30M | 16.20M | 16.30M | 16.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 171.30M | 143.80M | 140.40M | 171.80M | 209.00M |
| Operating Income | -22.60M | 87.30M | 500.00K | 50.40M | -14.30M |
| Income Before Tax | -50.70M | 57.60M | -16.80M | 92.70M | -27.60M |
| Income Tax Expenses | 3.90M | 6.40M | -4.80M | 24.70M | 3.70M |
| Earnings from Continuing Operations | -54.60M | 51.20M | -12.00M | 68.00M | -31.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.60M | 51.20M | -12.00M | 68.00M | -31.30M |
| EBIT | -22.60M | 87.30M | 500.00K | 50.40M | -14.30M |
| EBITDA | -100.00K | 110.30M | 23.50M | 75.20M | 11.00M |
| EPS Basic | -1.04 | 0.96 | -0.22 | 1.25 | -0.58 |
| Normalized Basic EPS | -0.54 | 0.80 | -0.21 | 1.12 | -0.38 |
| EPS Diluted | -1.04 | 0.91 | -0.22 | 1.19 | -0.58 |
| Normalized Diluted EPS | -0.54 | 0.76 | -0.21 | 1.06 | -0.38 |
| Average Basic Shares Outstanding | 52.40M | 53.20M | 54.20M | 54.40M | 54.20M |
| Average Diluted Shares Outstanding | 52.40M | 56.50M | 54.20M | 57.30M | 54.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |